OTS514 manufacturers
- OTS514
-
- $155.00 / 5mg
-
2026-01-20
- CAS:1338540-63-8
- Min. Order:
- Purity: 99.62%
- Supply Ability: 10g
- OTS514
-
- $8.00 / 1kg
-
2025-09-25
- CAS:1338540-63-8
- Min. Order: 1kg
- Purity: 99%
- Supply Ability: g-kg-tons, free sample is available
|
| | OTS514 Basic information | | Uses |
| Product Name: | OTS514 | | Synonyms: | CS-2532;OTS514;OTS 514;OTS-514;OTS514 HCl;9-[4-[(1R)-2-Amino-1-methylethyl]phenyl]-8-hydroxy-6-methylthieno[2,3-c]quinolin-4(5H)-one;Thieno[2,3-c]quinolin-4(5H)-one, 9-[4-[(1R)-2-amino-1-methylethyl]phenyl]-8-hydroxy-6-methyl-;cancer,Apoptosis,multiple,arrest,cycle,myeloma,OTS514,HMCL,inhibit,positive,Inhibitor,cell,TOPK;9-{4-[(2R)-1-aminopropan-2-yl]phenyl}-8-hydroxy-6-methyl-4H,5H-thieno[2,3-c]quinolin-4-one | | CAS: | 1338540-63-8 | | MF: | C21H20N2O2S | | MW: | 364.46 | | EINECS: | 604-604-1 | | Product Categories: | | | Mol File: | 1338540-63-8.mol |  |
| | OTS514 Chemical Properties |
| Boiling point | 501.3±50.0 °C(Predicted) | | density | 1.293±0.06 g/cm3(Predicted) | | solubility | DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS (pH 7.2) (1:2): 0.25 mg/ml | | form | A crystalline solid | | pka | 9.35±0.20(Predicted) | | color | Light yellow to yellow |
| | OTS514 Usage And Synthesis |
| Uses | OTS514 is a potent T-lymphokine-activated killer cell-originated protein kinase (TOPK) inhibitor. TOPK is involved with cancer cell proliferation and cancer stem cell maintenance. OTS514 also downregulates the oncogenic transcriptional factor, forkhead box protein M1 (FOXM1). | | Uses | OTS514 is a potent T-lymphokine-activated killer cell-originated protein kinase (TOPK) inhibitor. TOPK is involved with cancer cell proliferation and cancer stem cell maintenance. OTS514 also downregulates the oncogenic transcriptional factor, forkhead box protein M1 (FOXM1). | | in vivo | OTS514 (1-5 mg/kg; once a day for 2 weeks; intravenous administration) induces tumor regression in a xenograft model of A549 cells (TOPK-positive lung cancer cells)[1]. | Animal Model: | Female BALB/cSLC-nu/nu mice bearing a xenograft model of A549 cells[1] | | Dosage: | 1, 2.5, and 5 mg/kg | | Administration: | Intravenously treated; once every day for 2 weeks | | Result: | Resulted in tumor growth inhibition (TGI) of 5.7, 43.3, and 65.3% on day 15, respectively, without any body weight loss. |
|
| | OTS514 Preparation Products And Raw materials |
|